Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | RP-3500 |
| Synonyms | |
| Therapy Description |
RP-3500 binds to and inhibits ATR, which may lead to decreased downstream signaling and inhibition of tumor growth (PMID: 34911817). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RP-3500 | RP 3500|RP3500|Camonsertib | ATR Inhibitor 16 | RP-3500 binds to and inhibits ATR, which may lead to decreased downstream signaling and inhibition of tumor growth (PMID: 34911817). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM R3008H | prostate cancer | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a 29% tumor reduction in a castration-resistant prostate cancer patient harboring ATM R3008H, who remained on treatment for more than 61 weeks (PMID: 37277454; NCT04497116). | 37277454 |
| ATM inact mut | Advanced Solid Tumor | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a response rate of 12% (13/113), clinical benefit rate (CBR) of 42% (47/113) and median progression-free survival (mPFS) of 15 weeks in advanced solid tumor patients with inactivating mutations in DNA damage repair genes, including ATM with a CBR of 44.1% (15/34) and CBR was 54% (7/13) with biallelic vs 11% (1/9) with monoallelic ATM inactivation, and CBR of 75% and mPFS of 35 weeks in 20 ovarian cancer patients (PMID: 37277454; NCT04497116). | 37277454 |
| ATM Q628Pfs*7 ATM I1581Nfs*5 ATM A2843V | colon adenocarcinoma | sensitive | RP-3500 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RP-3500 inhibited viability in a colon adenocarcinoma cell line harboring ATM Q628Pfs*7, ATM I1581Nfs*5, and ATM A2843V in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 34911817). | 34911817 |
| RAD51C inact mut | ovarian cancer | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a partial response with complete resolution of the target lesion at 19 weeks in a patient with ovarian cancer harboring a RAD51C inactivating mutation (PMID: 37277454; NCT04497116). | 37277454 |
| ATM Q1919P | lung non-small cell carcinoma | sensitive | RP-3500 | Preclinical - Cell culture | Actionable | In a preclinical study, RP-3500 inhibited viability in a non-small cell lung cancer cell line harboring ATM Q1919P in culture (PMID: 34911817). | 34911817 |
| ATM R2832C | mantle cell lymphoma | sensitive | RP-3500 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RP-3500 inhibited viability in a mantle cell lymphoma cell line harboring ATM R2832C in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 34911817). | 34911817 |
| ATM loss | stomach cancer | sensitive | RP-3500 | Preclinical - Pdx | Actionable | In a preclinical study, RP-3500 resulted in complete tumor regression in a gastric cancer patient-derived xenograft (PDX) model with biallelic loss of ATM (PMID: 34911817). | 34911817 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05566574 | Phase Ib/II | RP-3500 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | Recruiting | USA | 0 |
| NCT04497116 | Phase Ib/II | RP-3500 + Talazoparib RP-3500 | Study of RP-3500 in Advanced Solid Tumors | Recruiting | USA | GBR | CAN | 1 |
CKB BOOST